Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

36.8%

84 terminated/withdrawn out of 228 trials

Success Rate

54.6%

-31.9% vs industry average

Late-Stage Pipeline

7 trials in Phase 3/4

Results Transparency

71%

72 of 101 completed trials have results

Key Signals

28 recruiting72 with results70 terminated14 withdrawn

Enrollment Performance

Analytics

Phase 2

61(35.9%)

Phase 1

46(27.1%)

N/A

45(26.5%)

Early Phase 1

11(6.5%)

Phase 3

4(2.4%)

Phase 4

3(1.8%)

170Total

Phase 2(61)

Phase 1(46)

N/A(45)

Early Phase 1(11)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (228)

Showing 20 of 228 trials

NCT06915454Not ApplicableRecruiting

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Role: lead

NCT06828588Early Phase 1Recruiting

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Role: lead

NCT05747625Phase 1Recruiting

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT06819228Early Phase 1Recruiting

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Role: lead

NCT03181256Active Not Recruiting

Early Detection of Lung Cancer

Role: lead

NCT06074133Active Not Recruiting

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

Role: lead

NCT07188896Phase 2Recruiting

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Role: collaborator

NCT03962647Early Phase 1Completed

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Role: lead

NCT07210632Early Phase 1Recruiting

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Role: collaborator

NCT07217028Phase 1Not Yet Recruiting

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Role: lead

NCT05764395Phase 2Active Not Recruiting

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Role: lead

NCT05361720Phase 2Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Role: lead

NCT00898313Recruiting

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Role: lead

NCT06638398Not ApplicableActive Not Recruiting

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

Role: lead

NCT07460765Phase 1Not Yet Recruiting

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Role: lead

NCT05901545Phase 1Recruiting

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Role: lead

NCT06105801Phase 4Recruiting

EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

Role: lead

NCT06593106Not ApplicableRecruiting

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Role: lead

NCT06922825Early Phase 1Withdrawn

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

Role: collaborator

NCT06016855Phase 4Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Role: lead